Navigation Links
Effective ADHD treatment found for children with fragile X syndrome
Date:2/18/2008

Fragile X syndrome (FXS) is the most common hereditary form of mental retardation. Many children with FXS also suffer from attention deficit and/or hyperactivity disorder (ADHD), which complicates social relationships at home and at school. Although stimulant medication such as Ritalin is often successfully used to treat children with ADHD, studies have shown that while it is effective in children with mental retardation, it also causes side effects such as increased irritability, decreased verbalization and social withdrawal.

A previous study showed that L-acetyl carnitine (LAC), a form of the amino acid carnitine, significantly reduced hyperactive behavior in FXS boys with ADHD who were treated with it for one year without causing adverse side effects. The same authors have now conducted a randomized, double-blind, placebo-controlled multicenter study to determine the effectiveness of LAC in a larger group. The study is published in the April 1st, 2008 issue of the American Journal of Medical Genetics Part A, available online via Wiley InterScience at http://www3.interscience.wiley.com/cgi-bin/jhome/33129.

Led by M. Giulia Torrioli and Giovanni Neri of the Universit Cattolica in Rome, the study involved 51 boys between 6 and 12 years old with FXS and ADHD who were treated in one of eight centers in Italy, France and Spain. Each patient followed the treatment for 12 months, which involved 500 milligrams of LAC or a placebo given twice daily. Patients were evaluated by an interdisciplinary team of child neuropsychiatrists and psychologists at the start of the study, after one month, six months and 12 months. The effects of the drug and placebo were evaluated using a set of neuropsychological tests to assess behavior.

Those treated with LAC demonstrated reduced hyperactive behavior and increased attention. No side effects were exhibited, confirming that LAC is a safe
'/>"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Blackwell Publishing Ltd.
Source:Eurekalert

Page: 1 2

Related biology news :

1. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
2. Safe and effective therapy discovered for patients with protein-losing enteropathy
3. Tamiflu effective for treatment and prevention of influenza in children 1 year and older
4. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
5. Quantitative PET imaging finds early determination of effectiveness of cancer treatment
6. New hope for horse lovers as effective control for killer ragwort is proposed
7. Trial seeks genetic fingerprint for predicting drug effectiveness
8. MIT model could improve some drugs effectiveness
9. New nanoparticle vaccine is more effective but less expensive
10. Socioeconomic position associated with effectiveness of HIV drugs
11. UC health news: molecular pathway may predict chemotherapy effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/25/2015)... Feb. 25, 2015  ABC Financial Services (ABC), ... the Health and Fitness Industry, today announced enhancements ... MYiCLUBonline.  The latest upgrade includes advances to the ... cardless check-in via Identity One fingerprint biometrics. The ... through interactive displays at the International Health, Racquet ...
(Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
(Date:2/18/2015)... 18, 2015  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. , ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern ... Orlando, FL Wednesday, March 4, 2015 at 10.25 ... the live webcasts for these events, please visit Cepheid,s website ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Cepheid to Webcast Upcoming Financial Presentations 2
... with salty, undrinkable water for fish production is ... be an effective potential alternative livelihood for people ... drylands. In a report released today, researchers ... on Agricultural Research in Dryland Areas (ICARDA), and ...
... CLEVELAND November 10, 2008 A multidisciplinary research team ... Ph.D., a professor in the School of Medicine,s Department ... a number of birth defects that affect the development ... jaw, palate, brain and heart are relatively common congenital ...
... of invasive marine is one of many research results ... the First World Conference on Marine Biodiversity, Ciudad de ... report that invasive species of marine macroalgae spread at ... that covered by invasive terrestrial plants. The difference ...
Cached Biology News:'Arid aquaculture' among livelihoods promoted to relieve worsening pressure on world's drylands 2'Arid aquaculture' among livelihoods promoted to relieve worsening pressure on world's drylands 3'Arid aquaculture' among livelihoods promoted to relieve worsening pressure on world's drylands 4'Arid aquaculture' among livelihoods promoted to relieve worsening pressure on world's drylands 5Case Western Reserve University uncovers genetic basis for some birth defects 2Marine invasive species advance 50km per decade, World Conference on Marine Biodiversity told 2Marine invasive species advance 50km per decade, World Conference on Marine Biodiversity told 3Marine invasive species advance 50km per decade, World Conference on Marine Biodiversity told 4
(Date:3/4/2015)... 2015  BioClinica®, Inc., a leading specialty ... announced that clinical trial professionals representing 20 ... annual European User Conference in ... use of its eClinical technologies to overcome ... the Microsoft Office-Smart OnPoint CTMS; Express EDC; ...
(Date:3/4/2015)... , March 4, 2015 ... Paris in December 2011, ... of yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular ... expected late 2016.   SARAH, a large ... cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, ...
(Date:3/3/2015)... 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, ... molecular diagnostics that target the underlying mechanisms of cancer, ... period ended December 31, 2014. Effective July ... from May 31 to December 31. As a result ... are for the quarter and the seven months ended ...
(Date:3/3/2015)... 03, 2015 Experts and industry insiders ... one event: the Alltech REBELation exploring innovation, inspiration and ... Now in its 31st year, Alltech’s annual international conference ... and the opportunity to join the REBELation at an ... 11:59 p.m. EST, at which point the standard early ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... Md., Aug. 6 ImQuest BioSciences announced,today ... National Institutes of,Health to support the development ... topical microbicide product. ImQuest and a consortium ... will,develop a highly innovative product from the ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" ... its pressure cycling technology ("PCT")-enhanced,trypsin digestion application for ... of products. Named "Proteolysis (Trypsin)-PrEP", this new,PCT-enhanced processing ... Development of Innovative Therapeutics Expo 2008, being held,this ...
... Integrated Nanochannel Chip and Reader for,Single-Molecule Mapping, Enabling Direct ... Strands of DNA in Context and ... BioNanomatrix, Inc., a developer,of breakthrough nanoscale whole genome ... today announced,receipt of a grant from the National Human ...
Cached Biology Technology:ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission 2ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission 3Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 2Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 3Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 4Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 5BioNanomatrix Awarded New NIH Grant for Development of Nanoscale Platform for Single-Molecule DNA Mapping and Haplotype Applications 2BioNanomatrix Awarded New NIH Grant for Development of Nanoscale Platform for Single-Molecule DNA Mapping and Haplotype Applications 3
... speeds, highest precision, more user-friendliness and absolute ... is the definition of the Mastercycler ep ... acid research has been developing dynamically. The ... PCR Systems. To keep pace with ...
... recent sequencing of Salmonella genomes has allowed ... ORFmer PCR* primer pairs. The S. enterica ... single chromosome (4,857,432 bp; 4,440 ORFs) and ... These ORFmers from Sigma-Genosys have been designed ...
... This kit is designed for easy ... The protocol allows for successful transformation simply ... kit reagents with cultured yeast cells. No ... washing, are required. The kit is particularly ...
... Bio-Stack Twister II Microplate Handler is ... solution for integrating BioTeks washers, readers ... expandable microplate capacity, ultimate flexibility and ... are adding capacity to single devices ...
Biology Products: